Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
CStone Pharmaceuticals HK$392.9 million placing of new shares
We advised CStone Pharmaceuticals on the placement
CureVac $250 million follow-on offering
We advised CureVac on the equity offering
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2026, 2033 and 2053
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Invacare chapter 11 filing
We are advising Highbridge Capital in connection with the restructuring
Integer Holdings $500 million convertible senior notes offering
The 2.125% convertible notes are due 2028
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering